A Phase 1, Randomized, Double-blind, Positive-controlled, Placebo-controlled, 4-Period Crossover, Thorough QT/QTc Study to Evaluate the Effect of Multiple Doses of BMS-986278 on Cardiac Repolarization in Healthy Participants
Latest Information Update: 02 Mar 2026
At a glance
- Drugs Admilparant (Primary)
- Indications Idiopathic pulmonary fibrosis; Liver disorders; Pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 02 Mar 2026 New trial record